Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
SEC filing
Biotech
J&J ends work on eczema drug, a $610M dent to ex-XBiotech asset
Johnson & Johnson will stop work in atopic dermatitis but continue in another skin disease with an ex-XBiotech monoclonal antibody it paid $750M for.
Kyle LaHucik
Feb 2, 2022 5:42pm
3-peat Friday: Castle Creek, Eliem and Adagio file for IPOs
Jul 19, 2021 8:57am
How Pandion went from a $65M Merck offer to a $1.9B done deal
Mar 5, 2021 9:09am
Denali, Odonate seek $273M Nasdaq IPOs
Nov 14, 2017 4:13am
Sinovac to go private amid bribery concerns
Jun 30, 2017 6:48am
CollPlant, Israel-based maker of regenerative tissue, files for $25M IPO
Oct 24, 2016 10:15am
